Progyny (NASDAQ: PGNY) is one of 27 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its competitors? We will compare Progyny to similar companies based on the strength of its risk, dividends, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Insider & Institutional Ownership
81.5% of Progyny shares are held by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 33.3% of Progyny shares are held by company insiders. Comparatively, 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Progyny and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Progyny has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Progyny’s competitors have a beta of 7.07, indicating that their average stock price is 607% more volatile than the S&P 500.
Valuation and Earnings
This table compares Progyny and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Progyny||$344.86 million||$46.46 million||355.56|
|Progyny Competitors||$1.94 billion||$96.17 million||42.17|
Progyny’s competitors have higher revenue and earnings than Progyny. Progyny is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and price targets for Progyny and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Progyny presently has a consensus price target of $43.40, suggesting a potential downside of 32.19%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 19.40%. Given Progyny’s competitors higher possible upside, analysts clearly believe Progyny has less favorable growth aspects than its competitors.
Progyny beats its competitors on 8 of the 13 factors compared.
Progyny Company Profile
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.